Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 9/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | HPN | P05981 | 2/20 | 0.41 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.41 |
| ▸ | CALCA | P06881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374601 | 1.00 | CCR1 (0.45) | CCR1TACR1ADAM17SCD5SCD | |
| SCHEMBL2375944 | 0.87 | MCHR1 (0.45) | TACR1 | |
| SCHEMBL2375951 | 0.87 | MCHR1 (0.45) | TACR1 | |
| SCHEMBL2376451 | 0.84 | DPP4 (0.46) | CCR1TACR1SCD5HPNHGFAC | |
| SCHEMBL2376445 | 0.84 | DPP4 (0.46) | CCR1TACR1SCD5HPNHGFAC | |
| SCHEMBL2374680 | 0.80 | POLB (0.51) | ADAM17ST14 | |
| SCHEMBL2374673 | 0.80 | POLB (0.51) | ADAM17ST14 | |
| SCHEMBL2373494 | 0.77 | GPR142 (0.44) | TACR1ADAM17 | |
| SCHEMBL2373502 | 0.77 | GPR142 (0.44) | TACR1ADAM17 | |
| SCHEMBL2375707 | 0.77 | FPR2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | CCR1 4595/4885TACR1 4560/4885ADAM17 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.